SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for CITIGROUP INC (C, C-PN) (CIK 0000831001) (C) — Feb 22, 2013

CITIGROUP INC (C, C-PN) (CIK 0000831001)
Date: Feb. 22, 2013 · CIK: 0000831001 · Accession: 0000000000-13-009956

AI Filing Summary & Sentiment

File numbers found in text: 333-172554

Referenced dates: April 12, 2012

Date
February 21, 2013
Author
Division of Corporation Finance
Form
UPLOAD
Company
CITIGROUP INC (C, C-PN) (CIK 0000831001)

Letter

February 21, 2013 Via E -mail Julie Bell Lindsay General Counsel -Capital Markets and Corporate Reporting Citigroup Inc. 399 Park Avenue New York, NY 10043

Re: Citigroup Funding Inc. 424 Prospectuses relating to Registration Statement on Form S -3 Filed March 2, 2011 File No. 333-172554

Dear Ms. Lindsay :

We have reviewed certain of your prospectus supplements for structured note offerings and your response s to our letter dated April 12, 2012 and considered our subsequent discussions with you. We have a number of comments that we have identified below . Please respond to this letter within ten business days confirm ing to us that you will comply with our comments in this letter and in our prior letter in your future prospectus supplements or explaining why you believe the comment is not appropriate . Please note that it is possible that we may have additional comments on the prospectus supplements you file in the future .

Pricing and Value of Structured Notes

We believe that, similar to the requirements of Regulation S -K Items 201, 501, and 505 for equity securities, the method by which the price of the structured not e being offered is determined through evaluation of its components and the value of such components should be described, particularly since the price and value of the structured note are not readily determinable from public information regarding your outst anding debt obligations. In our discussions, you have described the components of the public offering price of the structured note and the issuer’s or its affiliates’ estimate of the value of the structured note. Since you or your affiliates develop thes e valuations, we believe that it is important for investors to understand the difference between the original issue price of a structured note and its value as estimated by you or your affiliate in structuring the note and determining its pricing (the “issuer’s valuation”).

Julie Bell Lindsay Citigroup Inc. February 21 , 2013 Page 2

Issuer’s Valu ation

In order to clarify the disclosure for investors about the pricing and market value of the securities, w e believe you should prominently disclose, together with the price of the structured note as required by Item 501 of Regulation S -K, the issuer’s valuation of the structured note on the cover page of the prospectus. We believe that investors should be able to understan d the difference between the issuer’s valuation and the original issue price that they are paying for the structured note. In order for investors to understand this difference in a clear manner , we believe the issuer’s valuation that is disclosed should n ot include hedging costs (except in one limited circumstance described below), underwriting discounts or commissions and other transaction costs. In a typical structured note offering, we believe that t he disclosed issuer’s valuation should consist of a s ingle number that is comprised of the sum of the issuer’s valuation of the two components of the structured note: (1) the fixed income bond and (2) the embedded derivative (s). As discussed below, information about hedging and other costs also may be discl osed.

You may use n arrative disclosure to explain how you derive the issuer’s valuation of the structured note. For instance, if you include narrative disclosure, you could disclose that the issuer’s valuation is determined by using internal pricing mod els. In that case, it may be appropriate to narratively describe the pricing models and the relevant inputs and assumptions used in such models. As discussed below, narrative disclosure should include a discussion of the risks inherent in your valuation methodology and related assumptions .

It is our understanding that t he value of the fixed income bond component of the issuer’s valuation may reflect either (i) an interest rate that you determine you are willing to pay to issue similar debt securities (known as an “internal funding rate”) or (ii) an interest rate that reflects your secondary market credit spread s. We understand that the internal funding rate may represent a discount from your secondary market credit spreads. We have observed that issuers typically use an internal funding rate in calculating the value of the fixed income bond in order to account f or higher issuance, operational and ongoing management costs of structured notes in comparison to those costs for conventional fixed -rate debt, which is generally issued at an interest rate that reflects secondary market credit spreads . If the inter nal fu nding rate is used , we believe that you should include appropriate disclosure to describe how the use of an internal funding rate, rather than secondary market credit spreads , impacts the issuer’s valuation of the structured note. In addition, we believe that you should discuss in appropriate risk factor disclosure the risks that arise because this difference affects the value of the structured note at issuance as compared to the price of the structured note in the secondary market.

Julie Bell Lindsay Citigroup Inc. February 21 , 2013 Page 3

We have observed that when issuers value the embedded derivative component , they use valuation models that have various inputs. To develop these valuation models, issuers use traded market prices on comparable derivative instruments to derive the inputs for their embedded deriv ative valuation models ( customarily called “mid -market inputs”). These inputs can be used to estimate the value of other embedded derivatives that offer terms s imilar to the comparable traded derivative instruments. For structured notes, issuers generall y make adjustments to the mid-market inputs to estimate the value of a n embedded derivative that does not have an observable market price . Such inputs are generally determined in the same manner for financial statement reporting purposes. If you do not use mid -market inputs, we believe you should disclose this fact, describe what you use, and the risk that the embedded derivative is being valued differently than other similar derivatives .

In addition, except in one limited circumst ance noted below, we believe the disclosed valuation of the embedded derivative should not include “hedging costs” or other “transaction costs” of you or your affiliates arising from the issuance of the notes. We have observed that some issuers may use on ly a bidding process with unaffiliated third parties rather than internal pricing models to value the embedded derivative in the structured note . If you do not bid out the pricing of the embedded derivative to an unaffiliated third party or you use an int ernal pricing model to value the embedded derivative for any reason , the value of the embedded derivative should not include any hedging and other transaction costs of you or your affiliates . These costs should not be included because they are costs to yo u as the issuer separate from the value of the embedded derivative component. If you (i) bid out the pricing of the embedded derivative to an unaffiliated third party as the sole method of valuing the embedded derivative, (ii) do not use any internal pric ing model to value the embedded derivative for any reason and (iii) disclose in your prospectus that you will engage in the derivative transaction with such unaffiliated third party, then you may use the unaffiliated third party’s bid for valuing the embed ded derivative . We understand that the unaffiliated third party’s bid may already include their hedging costs. In this limited circumstance, your disclosure should indicate that the issuer’s valuation includes the unaffiliated third party’s estimated hed ging costs as part of its bid price for the embedded derivative .

Other Costs or Amounts

In addition to the disclosure of the issuer’s valu ation , we believe that as part of your pricing disclosures you should include narrative disclosure to explain (i) the fees, costs and other amounts that you add to the issuer’s valu ation to calculate the original issue price of the structured notes and (ii) whether those amounts received from investors are used or retained by you or an affiliate . As appropriate, you may quantify such disclosed fees, costs and other amounts.

Julie Bell Lindsay Citigroup Inc. February 21 , 2013 Page 4

Timing

Consistent with Securities Act Rule 159, w e believe that information about the issuer’s valuation should be conveyed to investors prior to the time of sale so that they can make an informed investment decision. If the structured notes are marketed using a preliminary prospectus or preliminary term sheet, and you use a range of the initial offering pri ce or pricing terms of the structured notes in such materials, then we understand you may also have developed a range of the issuer’s valuation of the structured notes , which also should be disclosed . In addition , you should provide sufficient disclosure in the preliminary prospectus or preliminary term sheet so that investors can assess the correlation between the range of the original issue price and the range of the issuer’s valuation .

Risk Factors

Depending upon the facts and circumstances of a parti cular offering, the p rospectuses for your structured note offerings may need to include risk factor disclosure1 relating to the pricing and valuation of the structured notes , as applicable, including:

 the risk that the issuer’s valu ation will be less than the original issue price ;  risks arising from the fact that the embedded derivative is not valued using mid -market inputs ;  risks to the effect that the use of an internal funding rate, rather than secondary market credit spreads, may result in a value of the structured note at issuance that is different from the price of the structured note in the secondary market;  the risk t hat secondary market prices will likely be lower than the original issue price because secondary market prices (i) take into account your secondary market credit spreads and (ii) exclude your costs of hedging your obligation on the notes, underwriting discounts and commissions and other transaction costs ;  any risks arising from the manner in which customer account statement values after issuance are determined and why these values may be temporarily higher than the secondary market values of the notes;  the factors that may affect secondary market prices such as changes in market conditions, your creditworthiness, and customary bid/ask spreads for similarly sized trades; and  any conflicts of interest arising from the determination of the structured note pric e, the issuer’s valuation, or the sale of the structured notes by an affiliate of the issuer.

1 See Item 503 of Regulation S -K.

Julie Bell Lindsay Citigroup Inc. February 21 , 2013 Page 5

Secondary M arket

We note that prospectuses disclose that the issuer or its affiliates may, but are not obligated to, make a secondary market in the structure d notes. We have observed that immediate ly following the issuance of structured notes, where there is disclosure that issuers or their affiliates may repurchase the notes, the price at which the issuer or its affiliates may initially repurchase structured notes may exceed the issuer’s valuation, the secondary market price of the notes , and the value of these notes on customer account statements. We understand that this temporary difference may occur because the repurchase price may include “reimbursement ” of (i) amounts that the issuer will not be using to hedge its future exposures on the notes, and (ii) other amounts that the issuer added to the issuer’s valuation to determine the price of the notes at initial issuance.

If applicable, w e beli eve that you should disclose why the price at which you or your affiliates may initially repurchase the notes may exceed the secondary market price for the notes. We also believe that you should disclose whether investors will always receive a higher repurchase price immediately after the issuance of the notes or whether it is discretionary. Further, since the time period for the temporary price difference is typically determined at the time of the initial pricing of the notes, you should disclose such ti me period and the reason for choosing the time period . We have observed that sometimes this time period is referred to as an “amortization” period. However, we believe this terminology may confuse investors. Instead, we believe you should use clear disc losure to explain to investors the reason for the potential temporary difference between the repurchase price, the issuer’s valuation, the secondary market price, and if applicable, the value on customer account statements.

If you have any questions r egarding these comments, please contact me or Raquel Fox at (202) 551 -3860.

Sincerely,
/s/ Amy Starr
Amy Starr
Chief
Office of Capital Markets Trends
Division of Corporation Finance

Show Raw Text
February 21, 2013

Via E -mail
Julie Bell Lindsay
General Counsel -Capital Markets and Corporate Reporting
Citigroup Inc.
399 Park Avenue
New York, NY 10043

Re: Citigroup Funding Inc.
424 Prospectuses relating to Registration Statement on Form S -3
Filed March 2, 2011
File No. 333-172554

Dear Ms. Lindsay :

We have reviewed certain of your prospectus supplements for structured note offerings
and your response s to our letter dated April 12, 2012  and considered our subsequent discussions
with you.  We  have a number  of comments  that we have identified below .  Please respond to this
letter within ten business days confirm ing to us that you will comply with our comments  in this
letter and in our prior letter  in your future prospectus supplements or explaining why you believe
the comment is not appropriate .  Please note that it is possible that we may have additional
comments  on the prospectus supplements you file in the future .

Pricing and Value of Structured Notes

We believe that, similar to the requirements of Regulation S -K Items 201, 501, and 505
for equity securities, the method by which the price of the structured not e being offered is
determined through evaluation of its components and the value of such components should be
described, particularly since the price and value of the structured note are not readily
determinable from public information regarding your outst anding debt obligations.  In our
discussions, you have described the components of the public offering price of the structured
note and the issuer’s or its affiliates’ estimate of the value of the structured note.  Since you or
your affiliates  develop thes e valuations, we believe that it is important for investors to
understand the difference between the original issue price of a structured note and its value as
estimated by you or your affiliate  in structuring the note and determining its pricing (the
“issuer’s valuation”).

Julie Bell Lindsay
Citigroup Inc.
February 21 , 2013
Page 2

 Issuer’s Valu ation

In order to clarify the disclosure for investors about the pricing and market value of the
securities, w e believe you should prominently disclose, together with the price of the structured
note as required by Item 501 of Regulation S -K, the issuer’s valuation  of the structured note  on
the cover page of the prospectus.  We believe that investors should be able to understan d the
difference between the issuer’s valuation and the original issue price that they are paying for the
structured note.  In order for investors to understand this difference in a clear manner , we believe
the issuer’s valuation that is disclosed should n ot include hedging costs (except in one limited
circumstance described below), underwriting discounts or commissions and other transaction
costs.   In a typical structured note offering, we believe that t he disclosed  issuer’s valuation
should consist of a s ingle number that is comprised of the sum of the issuer’s valuation of the
two components  of the structured note: (1) the fixed income bond and (2) the embedded
derivative (s).  As discussed below, information about hedging and other costs also may be
discl osed.

You may use n arrative disclosure  to explain how you derive the issuer’s valuation  of the
structured note.   For instance, if you include narrative disclosure, you could disclose that the
issuer’s valuation is determined by using internal pricing mod els.  In that case, it may be
appropriate to narratively describe the pricing models and the relevant inputs and assumptions
used in such models.  As discussed below, narrative disclosure should include a discussion of the
risks inherent in your valuation  methodology and related assumptions .

It is our understanding that t he value of the fixed income bond  component of the issuer’s
valuation  may reflect either (i) an interest rate that you determine you are willing to pay to issue
similar debt securities (known as an “internal funding rate”) or (ii) an interest rate that reflects
your secondary market credit spread s.  We understand that the internal funding rate may
represent a discount from your secondary market credit spreads.  We have observed that issuers
typically use an internal funding rate in calculating the value of the fixed income bond in order to
account f or higher issuance, operational and ongoing management costs of structured notes in
comparison to those costs for conventional fixed -rate debt, which is generally issued at an
interest rate that reflects secondary market credit spreads .  If the inter nal fu nding rate is used , we
believe that you should include appropriate disclosure to describe how the use of an internal
funding rate, rather than secondary market credit spreads , impacts the issuer’s valuation of the
structured note.  In addition, we believe that you should discuss in appropriate risk factor
disclosure the risks that arise because this  difference affects the value of the structured note at
issuance as compared to the price of the structured note in the secondary market.

Julie Bell Lindsay
Citigroup Inc.
February 21 , 2013
Page 3

 We have observed  that when issuers value the embedded derivative component , they use
valuation models that have  various inputs.   To develop these valuation models, issuers use traded
market prices on comparable derivative instruments to derive the inputs for their embedded
deriv ative valuation models ( customarily called “mid -market inputs”).  These inputs can be used
to estimate the value of other embedded derivatives that offer terms s imilar to the comparable
traded derivative instruments.   For structured notes, issuers generall y make adjustments to the
mid-market inputs to estimate the value of a n embedded  derivative that does not have an
observable market price .  Such inputs are generally determined in the same manner for financial
statement  reporting  purposes.   If you do not use mid -market inputs, we believe you should
disclose this fact, describe what you use, and  the risk that the embedded derivative is being
valued differently than other similar derivatives .

In addition, except in one limited circumst ance noted below, we believe the disclosed
valuation of the embedded derivative should not include “hedging costs” or other “transaction
costs” of you or your affiliates arising from the issuance of the notes.  We have observed that
some issuers may use on ly a bidding process with unaffiliated third parties rather than internal
pricing models to value the embedded derivative in the structured note .  If you do not bid  out the
pricing of the embedded derivative to an unaffiliated third party  or you use an int ernal pricing
model to value the embedded derivative for any reason , the value of the embedded derivative
should not include  any hedging and other transaction costs  of you or your affiliates .  These costs
should not be included because they are costs to yo u as the issuer separate from the value of the
embedded derivative component.  If you (i)  bid out the pricing of the embedded derivative to an
unaffiliated third party as the sole method of valuing the embedded derivative,  (ii) do not use any
internal pric ing model to value the embedded derivative for any reason and (iii) disclose in your
prospectus that you will engage in the derivative transaction with such unaffiliated third party,
then you may use the unaffiliated third party’s bid for valuing the embed ded derivative .  We
understand that the unaffiliated third party’s bid  may already include their hedging costs.   In this
limited  circumstance, your disclosure should indicate that the issuer’s valuation includes the
unaffiliated third party’s estimated hed ging costs as part of its bid price for the embedded
derivative .

Other Costs or Amounts

In addition to the disclosure of the issuer’s valu ation , we believe that as part of your
pricing disclosures you  should include narrative disclosure to explain (i)  the fees, costs and other
amounts that you add to the issuer’s valu ation  to calculate the original issue price of the
structured notes and (ii) whether those amounts received from investors are used or retained by
you or an affiliate .  As appropriate, you  may quantify such disclosed fees, costs and other
amounts.

Julie Bell Lindsay
Citigroup Inc.
February 21 , 2013
Page 4

 Timing

Consistent with Securities Act Rule 159, w e believe that information about the issuer’s
valuation  should be conveyed to investors prior  to the time of sale so that they can make an
informed investment decision.  If the structured notes are marketed using a preliminary
prospectus  or preliminary term sheet, and you use a range of the initial offering pri ce or pricing
terms of the structured notes in such materials, then we understand you may also have developed
a range of the issuer’s valuation  of the structured notes , which also should be disclosed .  In
addition , you should provide sufficient disclosure in the preliminary prospectus or preliminary
term sheet so that investors can assess the correlation between the range of the original issue
price and the range of the issuer’s valuation .

Risk Factors

Depending upon the facts and circumstances of a parti cular offering, the p rospectuses for
your structured note offerings may need to include risk factor disclosure1 relating to the pricing
and valuation of the structured notes , as applicable, including:

 the risk that the  issuer’s valu ation  will be less than the original issue price ;
 risks arising from the fact that the embedded derivative is not valued using mid -market
inputs ;
 risks to the effect that the use of an internal funding rate, rather than secondary market
credit spreads, may result in a value of the structured note at issuance that is different
from the price of the structured note in the secondary market;
 the risk t hat secondary market prices will likely be lower than the original issue price
because secondary market prices (i) take into account your secondary market credit
spreads and (ii) exclude your costs of hedging your obligation on the notes, underwriting
discounts and commissions and other transaction costs ;
 any risks arising from the manner in which customer account statement values after
issuance are determined and why these values may be temporarily higher than the
secondary market values of the notes;
 the factors that may affect secondary market prices such as changes in market conditions,
your creditworthiness, and customary bid/ask spreads for similarly sized trades; and
 any conflicts of interest arising from the determination of the structured note pric e, the
issuer’s valuation, or the sale of the structured notes by an affiliate of the issuer.

1  See Item 503 of Regulation S -K.

Julie Bell Lindsay
Citigroup Inc.
February 21 , 2013
Page 5

 Secondary M arket

We note that prospectuses disclose that the issuer or its affiliates  may, but are not
obligated to, make a secondary market in the structure d notes.  We have observed that
immediate ly following the issuance of structured  notes, where there is disclosure that issuers or
their affiliates may repurchase the notes, the price at which the issuer or its affiliates  may
initially repurchase structured notes may exceed the issuer’s valuation, the secondary market
price of the notes , and the value of these notes on customer account statements.  We understand
that this temporary difference may occur because the repurchase price may include
“reimbursement ” of (i) amounts that the issuer will not be using to hedge its future exposures on
the notes, and (ii) other amounts that  the issuer  added to the issuer’s valuation  to determine  the
price of the notes  at initial issuance.

If applicable, w e beli eve that you should disclose why  the price at which you  or your
affiliates may  initially repurchase the notes may exceed the secondary market price for the notes.
We also believe that you should disclose whether investors will always receive a higher
repurchase price immediately after the issuance of the notes or whether it is discretionary.
Further, since the  time period  for the temporary price difference  is typically determined at the
time of the  initial pricing of the notes, you should disclose such ti me period  and the reason for
choosing the time period .  We have observed that sometimes this time period is referred to as an
“amortization” period.  However, we believe this terminology may confuse investors.  Instead,
we believe you should use clear disc losure to explain to investors the reason for the potential
temporary difference between the repurchase price, the issuer’s valuation, the secondary market
price, and if applicable, the value on customer account statements.

If you have any questions r egarding these comments, please contact me or Raquel Fox at
(202) 551 -3860.

  Sincerely,

  /s/ Amy Starr
  Amy Starr
Chief
Office of Capital Markets Trends
Division of Corporation Finance